Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
301-315 of 362

Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®Insights from global key opinion leaders on optimizing patient care in NSCLC

Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
- advertisement

Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition

Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CEBringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers

Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence

Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
- advertisement

High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®High-Risk, HR+/HER2- EBC: Mastering Treatment Selection

Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens

Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®Treatment Intensification in HR+/HER2- EBC: Who and When?


































